复星医药：关于控股子公司药品注册申请获受理的公告

Core Points - Recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Zhaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration [1] Group 1 - The drug registration application pertains to a specific product, Compound Polyethylene Glycol (3350) Electrolyte Powder [1] - The acceptance of the application by the regulatory authority indicates a step forward in the product's market entry process [1]